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Objectives This study was designed to establish the direct vascular effects of apelin in vivo in man.
Background Apelin is the endogenous ligand for the previously orphaned G-protein–coupled receptor, APJ. This novel pathway
is widely expressed in the cardiovascular system and is emerging as an important mediator of cardiovascular
homeostasis. In pre-clinical models, apelin causes venous and arterial vasodilation.
Methods Vascular effects of apelin were assessed in 24 healthy volunteers. Dorsal hand vein diameter was measured by
the Aellig technique during local intravenous infusions (0.1 to 3 nmol/min) of apelin-36, (Pyr1)apelin-13, and
sodium nitroprusside (0.6 nmol/min). Forearm blood flow was measured by venous occlusion plethysmography
during intrabrachial infusions of apelin-36 and (Pyr1)apelin-13 (0.1 to 30 nmol/min) and subsequently in the
presence or absence of a “nitric oxide clamp” (nitric oxide synthase inhibitor, L-NG-monomethylarginine [8 mol/
min], coinfused with nitric oxide donor, sodium nitroprusside [90 to 900 ng/min]), or a single oral dose of aspi-
rin (600 mg) or matched placebo.
Results Although sodium nitroprusside caused venodilation (p  0.0001), apelin-36 and (Pyr1)apelin-13 had no effect on
dorsal hand vein diameter (p  0.2). Both apelin isoforms caused reproducible vasodilation in forearm resis-
tance vessels (p  0.0001). (Pyr1)apelin-13–mediated vasodilation was attenuated by the nitric oxide clamp
(p  0.004) but unaffected by aspirin (p  0.7).
Conclusions Although having no apparent effect on venous tone, apelin causes nitric oxide–dependent arterial vasodilation in
vivo in man. The apelin-APJ system merits further clinical investigation to determine its role in cardiovascular
homeostasis. (J Am Coll Cardiol 2008;52:908–13) © 2008 by the American College of Cardiology Foundation
ublished by Elsevier Inc. doi:10.1016/j.jacc.2008.06.013c
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spelin is the endogenous ligand for the orphan G-protein–
oupled receptor, APJ (1,2). The full-length mature pep-
ide, apelin-36, comprises 36 amino acids but the most
otent isoform is the pyroglutamated form of apelin-13,
Pyr1)apelin-13 (2–4). The APJ receptors are present on
ndothelial cells, vascular smooth muscle cells, and cardio-
yocytes (5).
In rodent models, exogenous apelin administration causes a
apid nitric oxide (NO)-dependent fall in blood pressure and
ean capillary filling pressure, indicating powerful vasodilator
nd venodilator effects (3). In ex vivo myography studies, apelin
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Manuscript received November 12, 2007; revised manuscript received March 26,
008, accepted June 3, 2008.auses NO-dependent vasorelaxation in human mesenteric
rteries (6) and venoconstriction in endothelium-denuded
uman saphenous veins (7). As a first step toward character-
zing the in vivo cardiovascular profile of apelin in man, we
ought to determine its direct vasomotor effects in the periph-
ral venous and arterial circulation.
ethods
ubjects. Twenty-four healthy male volunteers (age 19 to
4 years) participated following written informed consent,
ith the approval of the local research ethics committee,
nd in accordance with the Declaration of Helsinki. Partic-
pants were not taking regular medication and abstained
rom alcohol for 24 h and from food and caffeine-containing
rinks for at least 4 h before studies.
ascular studies. Studies were conducted in a quiet
emperature-controlled room (22°C to 25°C). Heart rate and
lood pressure were monitored at regular intervals with a
emiautomated, oscillometric sphygmomanometer (HEM
05CP, Omron, Tokyo, Japan).
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September 9, 2008:908–13 Vascular Effects of Apelin In Vivo in ManENOUS STUDIES. Intravenous infusions (0.25 ml/min)
ere administered through a 23-gauge needle in a non-
ranching dorsal hand vein (DHV). Venous tone was
easured by the Aellig technique during norepinephrine
Hospira, Illinois; 1 to 32 ng/min) preconstriction (50% to
0% reduction in diameter) as described previously (8). Six
ubjects (Fig. 1, protocol 1) received incremental infusions
f (Pyr1)apelin-13 or apelin-36 (Clinalfa AG, Läufelfingen,
witzerland; 0.1 to 3 nmol/min) followed, after saline
ashout, by a single dose of sodium nitroprusside (SNP)
Mayne Pharma Plc, Warwickshire, United Kingdom)
t 0.6 nmol/min. A further 3 subjects received
Pyr1)apelin-13 and apelin-36 in the absence of norepi-
ephrine preconstriction.
RTERIAL STUDIES. Intra-arterial infusions (1 ml/min)
ere administered through a 27-standard-wire-gauge steel
rachial artery needle. Forearm blood flow (FBF) was
easured in both forearms by venous occlusion plethysmog-
aphy as described previously (9,10). In protocol 2A, blood
amples (10 ml) were drawn from each arm into ethyl-
nediaminetetraacetic acid and centrifuged to obtain plasma
hat was stored at 80°C. Plasma apelin concentrations were
easured using a commercially available enzyme-linked im-
unosorbant assay (Phoenix Pharmaceuticals Inc., Burlin-
ame, California.). In protocol 3, a “NO clamp” (L-NG-
Figure 1 Study Design
Protocol 1: Dorsal hand vein infusions of (Pyr1)apelin-13 or apelin-36 (blue; nmol/
nephrine. Protocol 2 (A and B): Intrabrachial infusions of (Pyr1)apelin-13 or apelin
chial infusions of (Pyr1)apelin-13 (blue; nmol/min) and acetylcholine (yellow; g/m
placebo. L-NMMA  L-NG-monomethylarginine.onomethylarginine [8 mol/
in] coinfused with SNP [90 to
00 ng/min]) was used to allow
imulation of normal basal NO
ctivity during complete inhibition
f endogenous NO synthesis, as
escribed previously (11). Dispers-
ble aspirin (600 mg; Aspar Phar-
aceuticals Ltd., London, United
ingdom) was administered orally
0 min before study commence-
ent to inhibit production of
rostaglandins (12).
Eight subjects attended on 4
ccasions at least 1 week apart to receive incremental
nfusions of apelin-36 or (Pyr1)apelin-13 (0.1 to 30
mol/min) in the presence and absence of saline wash-
uts (protocol 2). A further 8 subjects attended on 4
ccasions to receive, in a randomized order: 1) the NO
lamp and oral aspirin; 2) the NO clamp and oral
lacebo; 3) saline placebo and oral aspirin; and 4) saline
lacebo and oral placebo, followed on all occasions by
equential infusions of (Pyr1)apelin-13 (0.3 to 3 nmol/
in) and acetylcholine (Novartis AG, Basel, Switzerland;
to 20 g/min) in a double-blind manner (protocol 3).
Abbreviations
and Acronyms
ANOVA  analysis of
variance
APJ  apelin receptor
AUC  area under the
curve
DHV  dorsal hand vein
FBF  forearm blood flow
NO  nitric oxide
SNP  sodium
nitroprusside
sodium nitroprusside (SNP) (red; nmol/min) and saline, with coinfusion of norepi-
lue; nmol/min) and saline with venous blood sampling (1). Protocol 3: Intrabra-
th coadministration of aspirin or placebo, and “nitric oxide clamp” or salinemin),
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Vascular Effects of Apelin In Vivo in Man September 9, 2008:908–13ata and statistical analyses. The DHV (13) and FBF
9) data were analyzed as described previously. The
ffects of the NO clamp and aspirin on FBF responses
o (Pyr1)apelin-13 and acetylcholine were assessed by
alculating area under the curve (AUC) using the trape-
oid method. Apelin concentrations were logarith-
ically transformed prior to analysis. Variables are
Figure 2 DHV Diameter During Coinfusion of Norepinephrine
DHV diameter during coinfusion of norepinephrine and (A) incremental doses of (P
and (B) incremental doses of apelin-36 (open squares) and single dose of SNP (o
hand vein; other abbreviations as in Figure 1.
Figure 3 Infused FBF
Infused FBF (A) in protocol 2A during infusion of (Pyr1)apelin-13 (top, solid square
incremental infusion of (Pyr1)apelin-13 (solid squares) versus apelin-36 (open squ
post-hoc Bonferroni tests. ANOVA  analysis of variance; FBF  forearm blood floeported as mean  standard error of mean and
nalyzed using repeated-measures analysis of variance
ANOVA) with post-hoc Bonferroni corrections, regres-
ion analysis, and 2-tailed Student t test as appropriate
Graph-Pad Prism, GraphPad Software, Inc., San Diego,
alifornia). Statistical significance was taken at the 5%
evel.
elin-13 (solid squares) and single dose of SNP (solid diamonds; 0.6 nmol/min)
amonds; 0.6 nmol/min). ***p  0.001, paired Student t test. DHV  dorsal
ay ANOVA) and apelin-36 (bottom, open squares; 1-way ANOVA) and (B) during
2-way ANOVA with repeated measures. *p  0.05, **p  0.01, ***p  0.001,yr1)ap
pen dis; 1-w
ares);
w.
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n all studies, apelin infusions were well tolerated with no
erious adverse events. There were no changes in heart rate
r blood pressure.
Neither (Pyr1)apelin-13 nor apelin-36 caused venoconstric-
ion in relaxed DHVs (data not shown). Following precon-
triction, DHV diameter was unaffected by (Pyr1)apelin-13
p  0.18, 1-way ANOVA) or apelin-36 (p  0.24, 1-way
NOVA) but increased by SNP (p  0.0001) (Fig. 2).
(Pyr1)apelin-13 and apelin-36 increased FBF in the
nfused arm (p  0.001) (Figs. 3 and 4). Vasodilation to
pelin-36 was dose-dependent (r2  0.41, p  0.0001) but
lateaued rapidly with (Pyr1)apelin-13 (r2  0.003, p 
.73). After continuous dose escalation of each apelin
soform, FBF declined gradually over 42 min (for both: p 
.0001, ANOVA). With apelin-36, FBF remained elevated
uring saline washout (p 0.0001) and failed to rise further
uring subsequent reinfusion (Fig. 3). With (Pyr1)apelin-13,
BF remained elevated at 6 min during saline washout (p 
.05) but not thereafter, and further vasodilation was demon-
trable during subsequent reinfusion (p  0.0001) (Fig. 3).
At the highest dose of 30 nmol/min, infused FBF was
reater with apelin-36 compared with (Pyr1)apelin-13
p  0.05) (Fig. 3B). The inclusion of saline washouts
etween doses did not affect vasodilation to either
Pyr1)apelin-13 (p  0.68) (Fig. 4B) or apelin-36 (p 
Figure 4 Infused FBF
Infused FBF (A) in protocol 2B during infusion of (Pyr1)apelin-13 (top, solid square
mental infusion of (Pyr1)apelin-13 (B) and apelin-36 (C) in the presence (solid squ
ANOVA with repeated measures). **p  0.01, ***p  0.001, post-hoc Bonferron.93) (Fig. 4C). With both apelin isoforms, FBF increasedn the noninfused arm (p 0.0001, ANOVA) at 30 nmol/min
p  0.05, post-hoc Bonferroni tests; data not shown).
Plasma apelin concentrations in the infused arm rose with
ncreasing doses of apelin-36 (p  0.0001) (Fig. 5) and
ncreased in the noninfused arm from 10 nmol/min (p 0.01).
L-NG-monomethylarginine reduced infused FBF (3.48 
.41 ml/100 ml/min to 2.10  0.17 ml/100 ml/min; p 
ay ANOVA) and apelin-36 (bottom, open squares; 1-way ANOVA) and during incre-
and absence (open squares) of saline washouts (for both: p  0.05, 2-way
. Abbreviations as in Figure 3.
Figure 5 Plasma Apelin Concentration
Plasma apelin concentration in venous blood samples from infused (solid
bars) and noninfused arm (open bars) during intrabrachial apelin-36 infusion.
**p  0.01, ***p  0.001, 1-way ANOVA with post-hoc Bonferroni tests.
Abbreviation as in Figure 3.s; 1-w
ares)
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Vascular Effects of Apelin In Vivo in Man September 9, 2008:908–13.001) but this was restored with SNP coinfusion (3.20
0.33 ml/100 ml/min; p  0.05 vs. baseline). Both
Pyr1)apelin-13 (p  0.001) and acetylcholine (p  0.001)
ncreased infused FBF (Fig. 6). Coinfusion of the NO
lamp inhibited the response to (Pyr1)apelin-13 (AUC: 4.7
0.9 AU vs. 1.7  0.7 AU; p  0.004) and acetylcholine
AUC: 12.8  2.3 AU vs. 6.4  1.5 AU; p  0.02) but
spirin had no effect (p  0.05 for both) (Fig. 6).
iscussion
his is the first study to examine the in vivo vascular actions of
pelin in man. Using robust well-validated techniques, we have
ssessed the direct effects of 2 endogenous apelin isoforms on
ascular tone. Although not affecting peripheral venous tone,
pelin peptides cause vasodilation in peripheral resistance
essels through a NO-dependent mechanism.
ffects of apelin on peripheral arteriolar tone. In keeping
ith pre-clinical models and studies of human mesenteric
essels in vitro, we have demonstrated that apelin causes
eproducible vasodilation in human forearm resistance vessels
n vivo. We studied 2 different apelin isoforms, apelin-36 and
Pyr1)apelin-13, and both caused a rapid onset of vasodilation.
pelin-36 exhibited a slower offset, with vasodilation persist-
ng for at least 42 min after cessation of infusion. This
rolonged offset of action is unusual but has been described
Figure 6 Infused FBF in Subjects During Infusion
Infused FBF in subjects during infusion of (top row) (Pyr1)apelin-13 in the presenc
(right) and (bottom row) acetylcholine in the presence (solid circles) or absence
dose responses to (Pyr1)apelin-13 and acetylcholine alone. For placebo versus NO
aspirin (AUC): (Pyr1)apelin-13, p  0.7; acetylcholine, p  0.9. AUC  area underith other agonists, such as the V2 agonist, desmopressin (14). vt is consistent with in vitro data showing that apelin-36
xhibits a much slower dissociation from the APJ receptor than
Pyr1)apelin-13 and causes prolonged biological activity in
icrophysiometric assays (4). In addition, apelin appears to be
apidly cleared from the circulation with a short plasma
alf-life of no longer than 8 min. Although shorter apelin
eptides have more potent depressor activity in rats (15), we
aw no difference in potency between the 2 isoforms and a
reater response to apelin-36 at the highest dose. This was due,
t least in part, to a plateauing of the response to
Pyr1)apelin-13 at higher doses that may have resulted from
PJ receptor internalization (16) combined with a shorter
uration of receptor activation.
Vasodilation to (Pyr1)apelin-13 was attenuated by two-
hirds during the NO clamp, indicating that vasodilation to
pelin is mediated predominantly by endothelial NO genera-
ion. As expected, the NO clamp also inhibited acetylcholine-
ediated vasodilation, which is known to be partly mediated
y NO (17). In contrast, systemic inhibition of prostanoid
eneration with oral aspirin did not alter vasodilation to either
Pyr1)apelin-13 or acetylcholine, alone or in combination with
he NO clamp. The dose of aspirin used in this study inhibits
radykinin-induced endothelial production of prostacyclin by
t least 85% (12), suggesting that prostanoids do not provide a
ajor contribution to apelin-mediated vasodilation. Our in
d squares) or absence (open squares) of nitric oxide (NO) clamp (left) or aspirin
circles) of NO clamp (left) or aspirin (right). p  0.0001; 1-way ANOVA for
(AUC): (Pyr1)apelin-13, p  0.01; acetylcholine, p  0.05. For placebo versus
rve; other abbreviations as in Figure 3.e (soli
(open
clamp
the cuivo findings are in close agreement with Salcedo et al. (6) who
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September 9, 2008:908–13 Vascular Effects of Apelin In Vivo in Manecently demonstrated that NO synthase, but not cyclooxygen-
se, inhibition attenuated relaxation to apelin in human mes-
nteric arteries in vitro.
ffects of apelin on peripheral venous tone. We demon-
trated constrictor and dilator responses to norepinephrine
nd SNP, respectively, and employed doses of apelin 10-
old higher than those required to cause vasodilation in the
orearm arterial circulation. It is unlikely therefore that the
ack of venous response to apelin reflected either inadequate
osing or sensitivity of the technique. However, we exam-
ned the effects of apelin in a single peripheral venous bed
nd cannot exclude the possibility of a direct effect on
entral capacitance veins. Further clinical studies are re-
uired to determine the in vivo effects of apelin in specific
enous beds and on overall systemic venous tone.
tudy limitations. We measured changes in FBF and
lasma apelin concentrations during local intrabrachial apelin
nfusions. At infusion rates3 nmol/min, we detected a rise in
lasma apelin concentrations accompanied by an increase in
BF in the noninfused arm, indicating spillover of infused
pelin into the systemic circulation. This spillover limits
nterpretation of blood flow changes at the higher doses of
pelin because of potential concomitant effects on myocardial
ontractility or activation of neurohumoral reflexes. However,
t apelin doses 3 nmol/min, changes in blood flow can be
olely ascribed to direct local vascular effects.
We have described the effects of exogenous apelin on
esistance vessels in the forearm vascular bed. Although con-
ordance between vasomotor responses in the forearm and
ther vascular beds is generally good (18), differences do exist
nd further studies will be needed to confirm our findings in
ther vascular beds such as the coronary circulation.
onclusions
e have shown that acute apelin administration in vivo in man
auses NO-mediated arterial vasodilation but does not appear
o affect peripheral venous tone. Increasing evidence from
re-clinical models has suggested that apelin-APJ signaling
ediates important effects on cardiovascular homeostasis. Our
ndings provide the strongest evidence to date of a role for the
pelin-APJ system in human cardiovascular regulation.
cknowledgments
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esearch Facility for their help with these studies.
eprint requests and correspondence: Dr. Alan G. Japp, Centre
or Cardiovascular Science, The University of Edinburgh, Chan-
ellor’s Building, Edinburgh, EH16 4SB, United Kingdom. E-
ail: alan.japp@ed.ac.uk.
KEFERENCES
1. O’Dowd BF, Heiber M, Chan A, et al. A human gene that shows
identity with the gene encoding the angiotensin receptor is located on
chromosome 11. Gene 1993;136:355–60.
2. Tatemoto K, Hosoya M, Habata Y, et al. Isolation and characteriza-
tion of a novel endogenous peptide ligand for the human APJ receptor.
Biochem Biophys Res Commun 1998;251:471–6.
3. Japp AG, Newby DE. The apelin-APJ system in heart failure:
pathophysiologic relevance and therapeutic potential. Biochem Phar-
macol 2008;75:1882–92.
4. Hosoya M, Kawamata Y, Fukusumi S, et al. Molecular and
functional characteristics of APJ. Tissue distribution of mRNA and
interaction with the endogenous ligand apelin. J Biol Chem
2000;275:21061–7.
5. Kleinz MJ, Skepper JN, Davenport AP. Immunocytochemical
localisation of the apelin receptor, APJ, to human cardiomyocytes,
vascular smooth muscle and endothelial cells. Regul Pept 2005;126:
233– 40.
6. Salcedo A, Garijo J, Monge L, et al. Apelin effects in human
splanchnic arteries. Role of nitric oxide and prostanoids. Regul Pept
2007;144:50–5.
7. Katugampola SD, Maguire JJ, Matthewson SR, Davenport AP.
[(125)I]-(Pyr(1))Apelin-13 is a novel radioligand for localizing
the APJ orphan receptor in human and rat tissues with evidence
for a vasoconstrictor role in man. Br J Pharmacol 2001;132:
1255– 60.
8. Aellig WH. A new technique for recording compliance of human
hand veins. Br J Clin Pharmacol 1981;11:237–43.
9. Newby DE, Wright RA, Ludlam CA, Fox KA, Boon NA, Webb DJ.
An in vivo model for the assessment of acute fibrinolytic capacity of the
endothelium. Thromb Haemost 1997;78:1242–8.
0. Newby DE, Wright RA, Labinjoh C, et al. Endothelial dysfunction,
impaired endogenous fibrinolysis, and cigarette smoking: a mechanism for
arterial thrombosis and myocardial infarction. Circulation 1999;99:
1411–5.
1. Stroes ES, Luscher TF, de Groot FG, Koomans HA, Rabelink TJ.
Cyclosporin A increases nitric oxide activity in vivo. Hypertension
1997;29:570–5.
2. Heavey DJ, Barrow SE, Hickling NE, Ritter JM. Aspirin causes
short-lived inhibition of bradykinin-stimulated prostacyclin produc-
tion in man. Nature 1985;318:186–8.
3. Haynes WG, Strachan FE, Webb DJ. Endothelin ETA and ETB
receptors cause vasoconstriction of human resistance and capacitance
vessels in vivo. Circulation 1995;92:357–63.
4. Affolter JT, McKee SP, Helmy A, Jones CR, Newby DE, Webb
DJ. Intra-arterial vasopressin in the human forearm: pharmacody-
namics and the role of nitric oxide. Clin Pharmacol Ther 2003;74:
9 –16.
5. Tatemoto K, Takayama K, Zou MX, et al. The novel peptide apelin
lowers blood pressure via a nitric oxide-dependent mechanism. Regul
Pept 2001;99:87–92.
6. Zhou N, Fan X, Mukhtar M, et al. Cell-cell fusion and internal-
ization of the CNS-based, HIV-1 co-receptor, APJ. Virology
2003;307:22–36.
7. Calver A, Collier J, Vallance P. Inhibition and stimulation of nitric
oxide synthesis in the human forearm arterial bed of patients with
insulin-dependent diabetes. J Clin Invest 1992;90:2548 –54.
8. Wilkinson IB, Webb DJ. Venous occlusion plethysmography in
cardiovascular research: methodology and clinical applications. Br J
Clin Pharmacol 2001;52:631–46.ey Words: apelin y APJ receptor y endothelium y vasodilator.
